Acute renal insufficiency during telavancin therapy in clinical practice

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 723-726

  Marcos, Luis A ^a   Camins, Bernard C ^a   Ritchie, David J ^b   Casabar, Ed ^b   Warren, David K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Daptomycin non susceptible S. aureus; Methicillin resistant Staphylococcus aureus; Nephrotoxicity; Vancomycin intermediate S. aureus

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TELAVANCIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY INFECTION; LONG TERM CARE; MALE; NEPHROTOXICITY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACUTE KIDNEY INJURY; ADULT; AGED; AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS;

EID: 84856967473     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr518     Document Type: Article

References (8)

1. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 1127-34.
2. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 2010; 54: 5376-8.
3. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010; 65: 1315-6.
4. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-92.
5. Stryjewski ME, Chu VH, O'Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50: 862-7.
6. Stryjewski ME, Graham DR, Wilson SE et al. on behalf of the Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93.
7. Rubinstein E, Lalani T, Corey G et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52: 31-40.
8. Coresh J, Stevens LA. Kidney function estimating equations: where do we stand? Curr Opin Nephrol Hypertens 2006; 15: 276-84.